drugset / Trial / NCT02256514
Open Label Trial of Immunotherapy for Advanced Liver Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate daily dosing of oral immunotherapy hepcortespenlisimut-L (V5) in patients with advanced stage of HCC not amenable to surgical intervention or with recurrent tumor after surgery.
Timeline
- Start
- 2014-09
- Primary completion
- 2019-09
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hepcortespenlisimut-L | Vaccine | 850 mg | Oral |